论文部分内容阅读
长链非编码RNA(lncRNA)在疾病的发生发展过程中发挥着重要的作用.LncRNA的异常表达与许多肿瘤的发生发展密切相关.本研究通过分析肿瘤基因图集(TCGA)数据库首次鉴定出了在前列腺癌中高表达的长链非编码RNA LINC01126,并在前列腺癌样本和前列腺癌细胞系中得到了验证.通过进一步分析发现,LINC01126的表达量在肿瘤中显著上调(419例前列腺癌组织样本和52例癌旁组织样本,P<0.001),LINC01126表达与临床病理分级的相关性分析中,相比于癌旁组织,Gleason 8样本和Gleason 9样本中的LINC01126表达水平显著增加(52例癌旁组织样本;Gleason 8,n=44,P<0.001;Gleason 9,n=71,P<0.001).进一步的分析结果表明,LINC01126能够较好地指示前列腺癌的Gleason分级.相比于Gleason 6样本,Gleason 8样本和Gleason 9样本中的LINC01126表达水平上调(Gleason 6,n=30;Gleason 8,n=44,P<0.01;Gleason 9,n=71,P<0.05).同样,相比于Gleason 7样本,Gleason 8样本和Gleason 9样本中的LINC01126表达水平也显著增加(Gleason 7,n=193;Gleason 8,n=44,P<0.001;Gleason 9,n=71,P<0.001).LINC01126的表达水平与前列腺癌病理分期的相关性结果提示,LINC01126在发生转移的前列腺癌中的表达量更高,差异显著(T2a,T2b,T2c样本共144例,T3a,T3b,T4样本共194例,P<0.01).另外,还分析了与LINC01126共表达或相反表达的mRNA,作为其可能的调控基因,及其这些基因的生物学进程和相关的信号通路,表明LINC01126与前列腺癌发生发展具有潜在的生物学关联,有望成为前列腺癌的生物标志物.
Long-chain non-coding RNA (lncRNA) plays an important role in the development of the disease.The abnormal expression of LncRNA is closely related to the occurrence and development of many tumors.This study was first identified by analyzing the TCGA database The long-chain non-coding RNA LINC01126, which is overexpressed in prostate cancer, was validated in prostate cancer samples and prostate cancer cell lines.Further analysis revealed that LINC01126 expression was significantly upregulated in tumors (419 prostate cancer tissue samples and P <0.001). In the correlation analysis between LINC01126 expression and clinicopathologic grade, the expression level of LINC01126 in Gleason 8 and Gleason 9 samples was significantly higher than that in paracancerous tissues Gleason 8, n = 44, P <0.001; Gleason 9, n = 71, P <0.001) .Further analysis showed that LINC01126 could better indicate the Gleason grade of prostate cancer.Compared with Gleason 6 , Gleason 8 and Gleason 9 (Gleason 6, n = 30; Gleason 8, n = 44, P <0.01; Gleason 9, n = 71, P <0.05) Similarly, Gleason 7 sample, Gleason 8 sample The expression level of LINC01126 in Gleason 9 was also significantly increased (Gleason 7, n = 193; Gleason 8, n = 44, P <0.001; Gleason 9, n = 71, The results of staging showed that the expression of LINC01126 was significantly higher in metastatic prostate cancer (144 in T2a, T2b and T2c samples, 194 in T3a, T3b and T4 samples, P <0.01). , As well as the mRNAs co-expressed or otherwise expressed with LINC01126 as their possible regulatory genes and the biological processes and related signaling pathways of these genes, indicating that LINC01126 is potentially biologically relevant to the development of prostate cancer and is expected to be promising Become a biomarker of prostate cancer.